Jacobson Pharma Adds Excilor (?????) to Its Portfolio to Develop China Market with Vemedia (The Netherlands)

HONG KONG, CHINA -�Media
OutReach - 5 November 2019 – Jacobson Pharma Corporation Limited (“Jacobson
Pharma” or the  ”Company”; Stock Code:
2633), a leading company engaged in research,
development, production, marketing and sale of generic drugs and proprietary
medicines, announced today that its wholly-owned subsidiary Jacobson Medical (Hong Kong) Limited (“Jacobson”)
has signed an exclusive distribution agreement  (the “Agreement”) with Vemedia Shine
Limited (“Vemedia”) (a wholly-owned subsidiary of Versailles
B.V., a company
incorporated in the Netherlands) for the marketing and distribution
of  ”Excilor” (?????)
range of
products  in the market of Mainland
China.

 

Photo for product(s) of Excilor being currently sold in Hong Kong. Excilor (?????) is a leading over-the-counter brand in Hong Kong for nail and foot care. 

Jacobson
will be the exclusive distributor for Vemedia for the marketing, sales and
distribution of Vemedia’s highly recognised medicated nail and foot
care brand, namely “Excilor”?????, in the China market for
a term of ten
years.

 

Mr. Derek Sum,
Chairman and Chief Executive Officer of
Jacobson Pharma remarked, “The strategic
collaboration represents a sound leverage of strengths and resources between
Jacobson and Vemedia. By riding on its established market network, Jacobson
Pharma aims to build a strong position for the Excilor brand whilst tapping the fast-growing nail and foot care market in China.  It
is one of our strategic goals to maximize the value and market potential of the
Excilor brand and create synergies with Vemedia via a sustainable collaboration.”

 

The appointment of
Jacobson as the exclusive distributor of Excilor in the Mainland China will
enhance the product portfolio of Jacobson Pharma and further strengthen its
market position in capitalizing on the rising consumer demand for branded healthcare
products in the burgeoning market of China.

 

Jacobson Pharma has
been forging strategic collaborations with various
business partners. A case in point is the recently-formed joint venture alliance with Weisen-U (???-U?) and Flucur
Nebuliser (???????). The Group currently
possesses a portfolio of proprietary healthcare brands such as Po Chai Pills (?????), Ho Chai Kung Tji
Thung San (??????????), Contractubex Scar
Gel (???????), Flying Eagle Wood
Lok Medicated Oil (???????), Tong Tai Chung
Woodlok Oil (????????), Doan’s Ointment (???????), Saplingtan (?????), Shiling Oil (?????), and Col-gan
Tablet (?????).  

About Jacobson Pharma Corporation Limited (????????????Stock Code: 2633)

Jacobson Pharma is a leading generic drug company in Hong Kong. The Group’s
proprietary medicines, notably being Po Chai Pills (?????), Ho Chai Kung Tji Thung San (??????????), Contractubex Scar Gel (???????) , Flying Eagle Wood Lok Medicated Oil (???????), Tong Tai Chung Woodlok Oil (????????), Doan’s Ointment (???????), Saplingtan (?????), Shiling Oil (?????) and Col-gan Tablet (?????) have been widely recognised by the market.
The Group aims to enrich its portfolio through addition of high value-added products
covering sterile injections, oncology products as well as orphan drugs and
biosimilars. With its corporate
headquarters based in Hong Kong, the Group has also established its operating
subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming
a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma
has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June
2017. For more details about Jacobson Pharma, please visit the Group’s website:
http://www.jacobsonpharma.com

About Vemedia Shine Limited

Vemedia is a fast growing reputable consumer healthcare company
headquartered in Diemen, the Netherlands, marketing a portfolio of leading
self-medicated brands in certain European countries. Excilor, a well-recognized
brand under Vemedia, primes itself as the specialist in medical foot care and
enjoys a preeminent position in the over-the-counter (OTC) market for the
treatment of fungal nail infection.